We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zacks Earnings Trends Highlights: JPMorgan, and Wells Fargo
Read MoreHide Full Article
For Immediate Release
Chicago, IL – January 13, 2022 – Zacks Director of Research Sheraz Mian says, "Earnings season has actually gotten underway already, with results from 20 S&P 500 members out at this stage."
Q4 Earnings Season Gets Underway
Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>>
The 2021 Q4 reporting cycle will really get going with the January 14th quarterly reports from JPMorgan (JPM - Free Report) , Wells Fargo (WFC - Free Report) and others. But the earnings season has actually gotten underway already, with results from 20 S&P 500 members out at this stage.
These 20 index members include operators such as FedEx, Adobe and others that have fiscal quarters ending in November, which we count as part of our Q4 tally. By the time the big banks put a spotlight on the Q4 earnings season, we will have seen such early results from almost two dozen index members.
It is too early to draw any firm conclusions from the 20 index members that have reported already, but we are off to a good start. Total earnings for these 20 index members are up +29.3% from the same period last year on +12.8% higher revenues, with 85.0% beating EPS estimates and 90.0% topping revenue projections. This is better than what we saw from this same group of 20 companies in the preceding reporting cycle.
Looking at Q4 as a whole, total earnings for the quarter are expected to be up +19.9% from the same period last year on +11.9% higher revenues.
We remain positive in our earnings outlook, as we see the overall growth picture steadily improving, as the near-term logistical issues get addressed.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks Earnings Trends Highlights: JPMorgan, and Wells Fargo
For Immediate Release
Chicago, IL – January 13, 2022 – Zacks Director of Research Sheraz Mian says, "Earnings season has actually gotten underway already, with results from 20 S&P 500 members out at this stage."
Q4 Earnings Season Gets Underway
Note: The following is an excerpt from this week’s Earnings Trends report. You can access the full report that contains detailed historical actual and estimates for the current and following periods, please click here>>>
The 2021 Q4 reporting cycle will really get going with the January 14th quarterly reports from JPMorgan (JPM - Free Report) , Wells Fargo (WFC - Free Report) and others. But the earnings season has actually gotten underway already, with results from 20 S&P 500 members out at this stage.
These 20 index members include operators such as FedEx, Adobe and others that have fiscal quarters ending in November, which we count as part of our Q4 tally. By the time the big banks put a spotlight on the Q4 earnings season, we will have seen such early results from almost two dozen index members.
It is too early to draw any firm conclusions from the 20 index members that have reported already, but we are off to a good start. Total earnings for these 20 index members are up +29.3% from the same period last year on +12.8% higher revenues, with 85.0% beating EPS estimates and 90.0% topping revenue projections. This is better than what we saw from this same group of 20 companies in the preceding reporting cycle.
Looking at Q4 as a whole, total earnings for the quarter are expected to be up +19.9% from the same period last year on +11.9% higher revenues.
We remain positive in our earnings outlook, as we see the overall growth picture steadily improving, as the near-term logistical issues get addressed.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.
See these 7 breakthrough stocks now >>
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.